Quebec-based Medicago’s COVID-19 vaccine candidate has shown good preliminary results in a Phase 2 trial, and the company is optimistic it could be in a position to seek Health Canada authorization this summer. Participants in the trial showed antibody levels that were ten times those seen in patients recovered from COVID-19, which typically bodes well for vaccine effectiveness. There is currently a Phase 3 international trial with 30,000 participants underway, and if that is successful Health Canada authorization could be sought afterwards.